Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers

Full text
Author(s):
Di Filippo, Leonardo Delello [1] ; Azambuja, Juliana Hofstatter [2] ; Paes Dutra, Jessyca Aparecida [1] ; Luiz, Marcela Tavares [3] ; Duarte, Jonatas Lobato [1] ; Nicoleti, Luiza Ribeiro [1] ; Olalla Saad, Sara Teresinha [2] ; Chorilli, Marlus [1]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP - Brazil
[2] Univ Estadual Campinas, Hematol & Transfus Med Ctr, UNICAMP, BR-13083970 Campinas - Brazil
[3] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS; v. 168, p. 76-89, NOV 2021.
Web of Science Citations: 0
Abstract

Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBM has aggressive development, and the pharmacological treatment remains a challenge due to GBM anatomical characteristics' (the blood-brain barrier and tumor microenvironment) and the increasing resistance to marketed drugs, such as temozolomide (TMZ), the first-line drug for GBM treatment. Due to physical-chemical properties such as short half-life time and the increasing resistance shown by GBM cells, high doses and repeated administrations are necessary, leading to significant adverse events. This review will discuss the main molecular mechanisms of TMZ resistance and the use of functionalized nanocarriers as an efficient and safe strategy for TMZ delivery. GBM-targeting nanocarriers are an important tool for the treatment of GBM, demonstrating to improve the biopharmaceutical properties of TMZ and repurpose its use in anti-GBM therapy. Technical aspects of nanocarriers will be discussed, and biological models highlighting the advantages and effects of functionalization strategies in TMZ anti-GBM activity. Finally, conclusions regarding the main findings will be made in the context of new perspectives for the treatment of GBM using TMZ as a chemotherapy agent, improving the sensibility and biological anti-tumor effect of TMZ through functionalization strategies. (AU)

FAPESP's process: 20/12622-0 - Evaluation of the biological potential of nanostructured lipid carriers functionalized with cetuximab dispersed in mucoadhesive thermo-responsive hydrogels for intranasal administration of temozolomide in the treatment of Glioblastoma Multiforme
Grantee:Leonardo Delello Di Filippo
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 20/04133-9 - Predictors of severity and new treatments for bone marrow neoplasias: mechanisms by which quercetin, epigallocatechin 3-gallate, gallic acid, turmeric, artemisimine and derivatives modulate epigenetic changes and energy metabolism in myelodysplasia
Grantee:Juliana Hofstatter Azambuja
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 19/25125-7 - Nanoemulsions containing terpenes as potentials larvicides and repellents against Aedes aegypti (Linnaeus, 1762)
Grantee:Jonatas Lobato Duarte
Support Opportunities: Scholarships in Brazil - Doctorate